Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Drops By 37.7%

Ventyx Biosciences, Inc. (NASDAQ:VTYX) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 4,547,617 shares, a decline of 37.7% from the December 31st total of 7,294,699 shares. Approximately 7.8% of the company’s shares are sold short. Based on an average daily trading volume, of 9,715,154 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 9,715,154 shares, the short-interest ratio is presently 0.5 days. Approximately 7.8% of the company’s shares are sold short.

Ventyx Biosciences Price Performance

Shares of NASDAQ VTYX opened at $13.95 on Friday. Ventyx Biosciences has a one year low of $0.78 and a one year high of $25.00. The business’s 50-day moving average price is $10.59 and its two-hundred day moving average price is $6.41. The company has a market capitalization of $995.47 million, a P/E ratio of -9.30 and a beta of 1.23.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.13. On average, equities analysts anticipate that Ventyx Biosciences will post -2.09 EPS for the current year.

Insider Activity

In related news, insider John Nuss sold 12,675 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the sale, the insider owned 489,481 shares in the company, valued at approximately $3,778,793.32. This represents a 2.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the sale, the chief executive officer owned 2,372,863 shares of the company’s stock, valued at approximately $18,318,502.36. This trade represents a 1.96% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 14.49% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Affinity Asset Advisors LLC bought a new position in shares of Ventyx Biosciences during the 2nd quarter valued at $9,707,000. Vanguard Group Inc. raised its holdings in Ventyx Biosciences by 19.2% during the third quarter. Vanguard Group Inc. now owns 3,769,997 shares of the company’s stock valued at $11,725,000 after buying an additional 607,725 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Ventyx Biosciences in the second quarter worth about $5,129,000. Vestal Point Capital LP boosted its stake in shares of Ventyx Biosciences by 2.5% during the 3rd quarter. Vestal Point Capital LP now owns 2,050,000 shares of the company’s stock worth $6,376,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Ventyx Biosciences by 17.5% during the 3rd quarter. Millennium Management LLC now owns 1,651,794 shares of the company’s stock valued at $5,137,000 after acquiring an additional 246,040 shares during the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Wall Street Analyst Weigh In

VTYX has been the subject of a number of research analyst reports. Clear Str lowered Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 7th. Piper Sandler downgraded Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price objective for the company. in a research note on Thursday, January 8th. Oppenheimer lowered Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. Finally, Wells Fargo & Company reissued an “equal weight” rating and issued a $14.00 price target on shares of Ventyx Biosciences in a research report on Thursday, January 8th. Eight research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $14.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.